Spectral AI has secured FDA de novo classification, now authorized to launch sales in the U.S., bolstered by $86.6M in Project BioShield funding and plans for global expansion.
Spectral AI has secured FDA de novo classification, now authorized to launch sales in the U.S., bolstered by $86.6M in Project BioShield funding and plans for global expansion.